PubMed

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

Steffes MW, Sibley S, Jackson M, Thomas W.

Diabetes Care. 2003 Mar;26(3):832-6.PMID: 12610045 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.

[No authors listed]

Ann Intern Med. 1998 Apr 1;128(7):517-23.PMID: 9518395 [PubMed - indexed for MEDLINE]Related articlesFree article

Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.

[No authors listed]

Diabetes. 1997 Nov;46(11):1829-39.PMID: 9356033 [PubMed - indexed for MEDLINE]Related articles

The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.

[No authors listed]

Diabetes. 1996 Oct;45(10):1289-98.PMID: 8826962 [PubMed - indexed for MEDLINE]Related articles

Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group.

[No authors listed]

J Clin Endocrinol Metab. 1987 Jul;65(1):30-6.PMID: 2884229 [PubMed - indexed for MEDLINE]Related articles

The relevance of persistent C-peptide secretion in type 1 (insulin-dependent) diabetes mellitus to glycaemic control and diabetic complications.

Winocour PH, Jeacock J, Kalsi P, Gordon C, Anderson DC.

Diabetes Res Clin Pract. 1990 Apr;9(1):23-35.PMID: 2351037 [PubMed - indexed for MEDLINE]Related articles

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW.

Diabetes. 2004 Jan;53(1):250-64. Erratum in: Diabetes. 2004 Jul;53(7):1934. PMID: 14693724 [PubMed - indexed for MEDLINE]Related articlesFree article

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

[No authors listed]

N Engl J Med. 2000 Feb 10;342(6):381-9. Erratum in: N Engl J Med 2000 May 4;342(18):1376. PMID: 10666428 [PubMed - indexed for MEDLINE]Related articlesFree article

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

JAMA. 2003 Oct 22;290(16):2159-67.PMID: 14570951 [PubMed - indexed for MEDLINE]Related articlesFree article

Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.

[No authors listed]

Arch Ophthalmol. 1998 Jul;116(7):874-86. Erratum in: Arch Ophthalmol 1998 Nov;116(11):1469. PMID: 9682700 [PubMed - indexed for MEDLINE]Related articles

Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).

White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

J Pediatr. 2001 Dec;139(6):804-12.PMID: 11743505 [PubMed - indexed for MEDLINE]Related articles

Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.

[No authors listed]

J Pediatr. 1994 Aug;125(2):177-88.PMID: 8040759 [PubMed - indexed for MEDLINE]Related articles

Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.

White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM.

Arch Ophthalmol. 2008 Dec;126(12):1707-15.PMID: 19064853 [PubMed - indexed for MEDLINE]Related articlesFree article

The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

[No authors listed]

Diabetes. 1995 Aug;44(8):968-83.PMID: 7622004 [PubMed - indexed for MEDLINE]Related articles

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Maréchaud R, Bougnères P, Charbonnel B, Saï P.

Lancet. 2000 Aug 12;356(9229):545-9.PMID: 10950231 [PubMed - indexed for MEDLINE]Related articles

Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ.

Arch Intern Med. 2009 Jul 27;169(14):1307-16.PMID: 19636033 [PubMed - indexed for MEDLINE]Related articles

The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group.

[No authors listed]

Diabetes. 1986 May;35(5):530-45.PMID: 2869996 [PubMed - indexed for MEDLINE]Related articles

Metabolic effect of islet B-cell function in insulin-treated diabetes.

Gjessing HJ, Matzen LE, Iversen S, Faber OK, Frøland A.

Scand J Clin Lab Invest. 1989 Jun;49(4):337-43.PMID: 2662383 [PubMed - indexed for MEDLINE]Related articles

Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients.

Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR.

Kidney Int. 2000 Oct;58(4):1742-50.PMID: 11012908 [PubMed - indexed for MEDLINE]Related articlesFree article

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article